Ignite Creation Date:
2025-12-24 @ 4:36 PM
Ignite Modification Date:
2025-12-25 @ 2:26 PM
Study NCT ID:
NCT03579966
Status:
TERMINATED
Last Update Posted:
2024-05-07
First Post:
2018-06-05
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Sponsor:
Catalyst Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-11
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-08-05
Completion Date Type:
ACTUAL
First Submit Date:
2018-06-05
First Submit QC Date:
None
Study First Post Date:
2018-07-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-03-12
Results First Submit QC Date:
None
Results First Post Date:
2024-05-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-15
Last Update Post Date:
2024-05-07
Last Update Post Date Type:
ACTUAL